Presentations and interviews
BioStock Life Science Fall Summit video | Oct 2023
BioStock Investor Meeting Presentation Sep 2023
BioStock Life Science Spring Summit 2023, 31 May 2023
Biostock interviews CEO Pernilla Sandwall, March 27 2023
Biostock presentation Investor summit, March 16 2023
Presentation of the ad hoc observations in the phase 2 study NeoFox, January 2023
BioStock interviews Professor Tommy Andersson and CEO Pernilla Sandwall about the findings and the revised study plan, December 2022
Pernilla Sandwall presents the company at the Biostock life science fall summit where also professor Tommy Andersson explains the unexpected observations, 8 december 2022
BioStock interview with WntResearch’s CEO Pernilla Sandwall, September 28, 2022
CEO Pernilla Sandwall at Biostock Investor Meeting, September 14, 2022
CEO Pernilla Sandwall at BioStock Life Science Spring Summit June 9, 2022
Investor presentation March 2021
”Sitdown” interview with Peter Morsing, CEO
27 February 2019
WntResearch holds presentation at Stockholm Corporate Finance Life Science Seminarium
7 March 2018
Information material presented by acting CEO Ulf Björklund at the extraordinary general meeting
20 September 2017
Presentation at Stockholm Corporate Finance Life Science Seminar
22 March 2017
Presentation at Investor Dagen in Copenhagen
21 March 2017
Presentation at Biotech Showcase in San Francisco
11 January 2017
Aktiespararna Stockholm Vasa and Financial Stockholm
25 October at 18:00
Aktiespararna, Malmö Centrum
May 11, 2016
Interview with CEO Henrik Lawaetz
March 16, 2016
Sedermeradagen, Lund
March 16, 2016
Stockholm Corporate Finance, Stockholm
March 10, 2016
Video from presentation of WntResearch at Stockholm Corporate Finance
CEO Henrik Lawaetz and CSO Tommy Andersson presented the company at Stockholm Corporate Finance Life Science & Healthcare Seminar at Operaterrassen in Stockholm, Thursday March 10.
LifeScienceDagen 2016, Gothenburg.
March 9, 2016
A commentary on the interim Foxy-5 phase 1 study report
The recent publication of an interim report of Foxy-5 clinical Phase 1 study has raised a lot of questions. This has prompted us to write a clarification on how WntResearch values the results obtained so far.
Short congress report
From AACR.NCI.EORTC Scientific meeting: Molecular Targets and Cancer Therapeutics in cancer, November 5-9, 2015 in Boston, USA with comments from CEO Nils Brünner
Foxy-5 – Preliminary Report: Phase I
Dose Escalating Study to Evaluate the
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of
Foxy-5 in Patients with Metastatic Breast, Colon or Prostate Cancer
November 6th, 2015
WntResearch at Sedermeradagen in Lund 26 March 2015
Speaker: Nils Brünner, VD
Annual General Assembly, Malmø, 09.06.15
Speaker: Nils Brünner, CEO